

Law Offices of
Dieterich & Associates

815 Moraga Drive

Suite 207

Los Angeles, California 90049

(310) 312-6888

FAX (310) 312-6680

venturelaw@gmail.com

Christopher Dieterich

Mike Khalilpour

Of Counsel

J. John Combs

December 23, 2024

OTC Markets Group

304 Hudson Street

Second Floor

New York, NY 10013

RE: *Legal Opinion concerning Adequate Current Information of*
Event Cardio Group, Inc.
(Symbol – ECGI)

Ladies/Gentlemen:

You are entitled to rely on this letter in determining whether Event Cardio Group, Inc. (the “Issuer”) has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933. Application of the Rule 144 exemption to trades is subject to the provisions of 144(i)(1).

I am a resident of the United States and have been retained by the Issuer for the purpose of rendering this letter and related matters. This firm’s relationship with the Issuer includes, over and above writing this letter, serving as special securities counsel for the Issuer, which duties include preparing or reviewing disclosure information and press releases, interfacing with the chief financial officer and independent accountants, and giving general legal advice to management. The firm does not own any shares of the Issuer’s securities and has no plans, agreements nor intention of receiving any such shares in the future, in payment for services.

I have examined such corporate records and other documents and such questions of law as I have considered necessary or appropriate for purposes of writing this letter. In all such examinations, I have assumed the genuineness of all signatures, the authenticity of all documents submitted to me as originals, the conformity to original documents of all documents submitted to me as copies and the authenticity of all originals of such documents submitted as copies. Further, in all such examinations, I may have relied on information obtained from public officials, officers of the Issuer, and other sources, and represent that all such sources are believed to be reliable.

This letter relates to the laws of the United States, specifically Federal securities law. I have been a member in good standing of the bar of the State of California since 1980, and am permitted to practice before the Securities and Exchange Commission (the “SEC”) and I have

not been prohibited from practice thereunder. I have not ever been suspended or barred from practicing in any state or jurisdiction, and I have not been charged in a civil or criminal case. Further, I am not currently, nor have I been in the past 5 years, the subject of an investigation, hearing or proceeding by the SEC, the US Commodity Futures Trading Commission, FINRA or any other federal, state or foreign regulatory agency. I have never been suspended or barred from practicing in any state or jurisdiction, and I have not been charged in a civil or criminal case.

The Issuer is not a reporting company and, therefore, does not file annual or other reports with the SEC. I have reviewed publicly available information relating to the Issuer Including:

- (i) the Issuer's profile posted on the OTC Markets Group website;
- (ii) its Initial Company information and Disclosure Statement filed as an Annual Statement for the year ended August 31, 2018 with the OTC Markets Group on June 3, 2019, unaudited;
- (iii) its unaudited financial statements for the period ended November 30, 2018, filed with the OTC Markets Group on July 11, 2019;
- (iv) its unaudited financials statements for the period ended February 28, 2019, filed with the OTC Markets Group on June 3, 2019;
- (v) its unaudited interim Quarterly Report for the third quarter (May 31, 2019), filed with the OTC Markets Group on June 12, 2019;
- (vi) its unaudited Quarterly Reports for the first, second and third quarters, ending on November 30, 2019, February 29 and May 31, 2020, respectively, and filed with OTC Markets Group on January 15, April 14 and July 9, 2021, respectively;
- (vii) its unaudited Annual Report for the year ended August 31, 2020, filed with OTC Markets Group on October 29, 2020;
- (viii) its Supplemental Disclosure for Change of Control Events, filed on December 29, 2020 with OTC Markets Group;
- (ix) the Attorney Letter with Respect to Current Information, filed with the OTC Markets Group on January 13, 2021;
- (x) its unaudited Quarterly Reports for the first, second and third quarters, ending on November 30, 2020, February 28 and May 31, 2021, respectively, and filed with OTC Markets Group on January 21, June 23 and August 11, 2021, respectively;
- (xi) its unaudited Annual Report for the year ended August 31, 2021, filed with OTC Markets Group on November 24, 2021;
- (xii) its unaudited Quarterly Reports for the first, second and third quarters, ending on November 30, 2021, February 28 and May 31, 2022, respectively, and filed with OTC Markets Group on January 19, April 19 and July 19, 2022, respectively;
- (xiii) its unaudited Annual Report for the year ended August 31, 2022, filed with OTC Markets Group on January 9, 2023;
- (xiv) its unaudited Quarterly Reports for the first, second and third quarters, ending on November 30, 2022, February 28 and May 31, 2023, respectively, and filed with OTC Markets Group on January 26, April 19 and September 26, 2023, respectively;
- (xv) its unaudited Annual Report for the year ended August 31, 2023, filed with OTC Markets Group on December 28, 2023, then amended January 10, 2024 and Re-Amended on January 15, 2024; and

(xvi) its unaudited Quarterly Report for the period ended November 30, 2023, filed with OTC Markets Group on January 15, 2024;

(xvii) its unaudited Quarterly Reports for the second and third quarters, ending on February 29 and May 31, 2024, respectively, and filed with OTC Markets Group on April 22 and July 19, 2024, respectively, and

(xviii) its unaudited Annual Report for the year ended August 31, 2024, filed with OTC Markets Group on December 16, 2024.

All of the above reports constitute the “Information” available to the public. The Company’s financial statements provided in the Information have not been audited through December 16, 2024.

The entity or individual responsible for the preparation and compilation of the financial statements contained in the Information is Jamie Steigerwald. He started in the mortgage brokerage business in 2003, but following the 2008 mortgage crisis, he shifted into consulting and became a principal in various industries, to include marketing, sales and operations. Since July of 2012, he has owned SwiftLead, Inc., a sales and marketing firm, 3JE, Inc., an AT&T Direct TV and cellphone reseller, and ESSRW, an equestrian equipment manufacturer and repairer. His financial education was earned in the mortgage industry and expanded throughout the intervening 15 years. Prior to becoming an officer and director of the Company, he was the Chief Operating officer for Sugarmade, Inc. an OTC-listed public company.

It is my opinion that the Information (i) constitutes adequate current public information concerning the Issuer’s securities and it is available within the meaning of Rule 144(c)(2) under the Securities Act of 1933; (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities pursuant to Rule 15c2-11 under the Securities Exchange Act of 1934 (the “Exchange Act”); (iii) complies as to form with the OTC Markets Group’s Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otcm Markets.com; and (iv) has been posted through the OTC Disclosure and News Service.

The Issuer’s transfer agent is Pacific Stock Transfer Co., 6725 Via Austi Parkway, Suite 300, Las Vegas, Nevada 8919. Pacific Stock Transfer Co. is registered with the SEC. The method used to confirm the number of outstanding shares of common stock set forth in the Information was to contact the Issuer’s transfer agent and receive confirmation as to the number of outstanding shares. As of August 31, 2024, the total number of outstanding shares of common and preferred stock of the Issuer was 166,073,145 and 1 share, respectively. As of December 16, 2024, the total number of outstanding shares of common and preferred stock of the Issuer was 166,073,145 and 1 share, respectively. There was a change in control on October 30, 2023, with a change in officers and directors, as well as majority stockholders.

I have personally met, via telephone and internet, with Jamie Steigerwald, who is the President, Secretary and Chief Financial officer and Chairman of the Board of Directors, and the largest shareholder by voting rights, owning the single preferred share outstanding, which constitutes voting control of the entity. I have reviewed the Information published by the Issuer through the OTC Disclosure and News Service. I have discussed the Information with management and a majority of the directors of the Issuer.

To the best of my knowledge, after inquiry of management and the directors of the Issuer, neither counsel nor any officer, director or 5% holder of the securities of the Issuer is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

No person other than the OTC Markets Group is entitled to rely on this letter. However, I hereby grant the OTC Markets Group full and complete permission and rights to publish the letter through the OTC Disclosure and New Service for viewing by the public and regulators.

I have compiled a list below, as of December 16, 2024, of the names of each executive officer, director, other control persons of the Issuer, consultant or any other advisor of the Issuer who assisted, prepared or provided information with respect to the Issuer's disclosure or who received securities as consideration for services rendered to the Issuer and the following information related to each: (i) their full name, (ii) their business address, (iii) the number and class of the Issuer's securities beneficially owned by each of them (iv) with respect to each of the securities described in the preceding clause whether or not the certificate or other document that evidences the securities contains a legend stating that the securities have not been registered under the Securities Act and setting forth the referring to restrictions on transferability and sale of the securities and (v) a complete description of the consideration received by the Issuer in connection with each issuance of shares to any of them including, without limitation, the nature of any services performed for or on behalf of the Issuer. For purpose of this letter, the term "control person" includes (i) any person controlling, under common control with, or controlled by, the Issuer or (ii) any person who obtained securities of the Issuer in connection with a negotiation with the Issuer within the three-year period prior to the date of the opinion. With respect to any of the Issuer's control persons that is an entity and any parent entity of any control person, this letter provides the information described in the first sentence of this paragraph for each control person of such entity or parent entity.

(1) ***Name: Jamie Steigerwald, President, CEO and Chairman***

- (i) President, CEO and Chairman and sole director of the Board of Directors
- (ii) Steigerwald's Business Address: 9891 Irvine Center Drive, Suite 200, Irvine CA 92618
- (iii) Number and Class of Shares Beneficially Owned: 1 share of Preferred
- (iv) Shares are restricted
- (v) Acquired shares in exchange for cash

(2) ***Name: Xing Zhang***

- (i) Major Shareholder
- (ii) Zhang's Business Address: 626 Wilshire Boulevard, Suite 410, Los Angeles, CA 90017
- (iii) Number and Class of Shares Beneficially Owned: 13,333,333 Common Shares
- (iv) Shares are restricted
- (v) Acquired shares in exchange for securities in corporate acquisition of East-West, Inc.

I have made specific inquiry of each of the persons listed above, persons engaged in promotional

activities regarding the Issuer, and persons owning more than ten percent (10%) of the Securities (collectively, the “Insiders”), and based upon such inquiries and other information available to counsel, there were no sales of shares, but there were redemptions. Nothing has come to the attention of counsel indicating that any Insider is in possession of any material non-public information regarding the Issuer of the Securities that would prohibit any of them from buying or selling the Securities under Rules 10b-5 or 10b5-1 under the Exchange Act. This company is a “shell” as defined in Rule 405 of the Securities Act.

I trust this information complies with your request. If you need additional information please contact me.

Very truly yours,

DIETERICH & ASSOCIATES

/s/ *Chris Dieterich*

Christopher Dieterich